Search research articles
Contact Us
Filters
Showing results (301-310 of 594) with videos related to
Page
of 60
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
The Lancet. Oncology
|
August 17, 2023
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, et al.
The Lancet. Oncology
|
February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 21, 2025
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, et al.
Frontiers in Oncology
|
April 8, 2025
RAS70 peptide targets multiforme glioblastoma by binding to the plasma membrane heat shock protein HSP70
Maxim Shevtsov, Natalia Yudintceva, Danila Bobkov, et al.
The Lancet. Oncology
|
March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
P S Schmid, H L McArthur, J Cortés, et al.
Nature Medicine
|
August 25, 2022
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, et al.
Lancet (London, England)
|
February 14, 2021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, et al.
ACS Applied Bio Materials
|
July 6, 2022
Hybrid (Bovine Serum Albumin)/Poly(<i>N</i>-vinyl-2-pyrrolidone-<i>co</i>-acrylic acid)-Shelled Microbubbles as Advanced Ultrasound Contrast Agents
Tatyana M Estifeeva, Roman A Barmin, Polina G Rudakovskaya, et al.
Page
of 60
Search research articles
Search
Showing results (301-310 of 594) with videos related to
Sort By:
Page
of 60
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
The Lancet. Oncology
|
August 17, 2023
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, et al.
The Lancet. Oncology
|
February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 21, 2025
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, et al.
Frontiers in Oncology
|
April 8, 2025
RAS70 peptide targets multiforme glioblastoma by binding to the plasma membrane heat shock protein HSP70
Maxim Shevtsov, Natalia Yudintceva, Danila Bobkov, et al.
The Lancet. Oncology
|
March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2025
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
P S Schmid, H L McArthur, J Cortés, et al.
Nature Medicine
|
August 25, 2022
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, et al.
Lancet (London, England)
|
February 14, 2021
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, et al.
ACS Applied Bio Materials
|
July 6, 2022
Hybrid (Bovine Serum Albumin)/Poly(<i>N</i>-vinyl-2-pyrrolidone-<i>co</i>-acrylic acid)-Shelled Microbubbles as Advanced Ultrasound Contrast Agents
Tatyana M Estifeeva, Roman A Barmin, Polina G Rudakovskaya, et al.
Page
of 60